Completed PHASE3 INTERVENTIONAL 2-arm NCT00395993

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

Sponsor: American Regent, Inc.

Conditions Anemia

Interventions Ferric Carboxymaltose (FCM) Ferrous Sulfate tablets

Updated 9 times since 2017 Last updated: Jan 22, 2018 Started: May 31, 2005 Primary completion: Apr 30, 2006 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00395993, this PHASE3 trial focuses on Anemia and remains completed. Sponsored by American Regent, Inc., it has been updated 9 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Feb 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Feb 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Regent, Inc.

Data source: American Regent, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norristown, United States